CA3018081C - Administration d'un anticorps monoclonal anti-lgr5 - Google Patents

Administration d'un anticorps monoclonal anti-lgr5

Info

Publication number
CA3018081C
CA3018081C CA3018081A CA3018081A CA3018081C CA 3018081 C CA3018081 C CA 3018081C CA 3018081 A CA3018081 A CA 3018081A CA 3018081 A CA3018081 A CA 3018081A CA 3018081 C CA3018081 C CA 3018081C
Authority
CA
Canada
Prior art keywords
monoclonal antibody
lgr5
administration
cancer
18g7h6a3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3018081A
Other languages
English (en)
Other versions
CA3018081A1 (fr
Inventor
Christopher L. Reyes
Peter Chu
Elizabeth Doolin
Jose IGLESIAS
Original Assignee
Bionomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Inc filed Critical Bionomics Inc
Priority claimed from PCT/AU2017/050250 external-priority patent/WO2017161414A1/fr
Publication of CA3018081A1 publication Critical patent/CA3018081A1/fr
Application granted granted Critical
Publication of CA3018081C publication Critical patent/CA3018081C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne d'une manière générale le domaine de la biologie du cancer. Certains modes de réalisation des méthodes et des compositions décrits ici concernent l'administration d'anticorps humanisés ou de fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement à LRG5 pour traiter certains cancers.
CA3018081A 2016-03-22 2017-03-21 Administration d'un anticorps monoclonal anti-lgr5 Active CA3018081C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311631P 2016-03-22 2016-03-22
US62/311,631 2016-03-22
PCT/AU2017/050250 WO2017161414A1 (fr) 2016-03-22 2017-03-21 Administration d'un anticorps monoclonal anti-lgr5

Publications (2)

Publication Number Publication Date
CA3018081A1 CA3018081A1 (fr) 2017-09-28
CA3018081C true CA3018081C (fr) 2025-09-23

Family

ID=

Similar Documents

Publication Publication Date Title
US20240360241A1 (en) Humanized antibodies that bind lgr5
US10745487B2 (en) Method of treating cancer by administering an anti-LGR5 monoclonal antibody
JP2021524240A (ja) 二重特異性抗体の組成物及びその使用方法
HUE030103T2 (en) A pharmaceutical composition for the treatment and / or prevention of cancer
EP4077389A1 (fr) Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique
AU2016310348A1 (en) Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
JP2021511372A (ja) Ｔｉｍ３に対する抗体で癌を処置する方法
KR20210106531A (ko) 암 치료를 위한 조성물 및 방법
TW202340243A (zh) 抗ｃｄ３９抗體及其用途
CA3018081C (fr) Administration d'un anticorps monoclonal anti-lgr5
US20240034788A1 (en) Abscopal therapy for cancer
HK1261816A1 (zh) 抗lgr5单克隆抗体的施用
HK1234072B (en) Humanized antibodies that bind lgr5
HK1234072A1 (en) Humanized antibodies that bind lgr5
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
HK40113788A (zh) 抗cd39抗体及其用途